Basic Information
Zokinvy
Regulatory Information
EMEA/H/C/005271
July 18, 2022
May 19, 2022
3
November 9, 2023
Company Information
Ireland
G24A Arc Labs Research and Innovation Centre SETU West Campus, Carriganore Waterford X91 P20H
Tmc Pharma (Eu Ltd.
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.
Overview Summary
Zokinvy is a medicine used to treat patients of 12 months and older who are affected by the following rare diseases in which features resembling aging appear in childhood: - Hutchinson-Gilford progeria syndrome; - processing-deficient progeroid laminopathies. The diseases that Zokinvy is used to treat are rare and Zokinvy was designated as ‘orphan medicine’ on [14 December 2018](/en/medicines/human/orphan-designations/eu-3-18-2118) for Hutchinson-Gilford progeria syndrome. Zokinvy contains the active substance lonafarnib.